

I am researching the incidence and treatment of breast cancer. Could you please provide the number of patients that you have treated in the past three months with the following:

Abemaciclib + Anastrozole/Exemestane/Letrozole 0

- Abemaciclib + Fulvestrant 0
- Alpelisib + Fulvestrant not in data
- Atezolizumab 0
- Bevacizumab not in data
- Eribulin <5
- Everolimus + Exemestane 0
- Fulvestrant as a single agent <5 (time period is Sep to Nov)
- Gemcitabine + Paclitaxel 0
- Lapatinib not in data
- Neratinib 0
- Olaparib not in data
- Palbociclib + Anastrozole/Exemestane/Letrozole <5
- Palbociclib + Fulvestrant 0
- Pertuzumab + Trastuzumab + Docetaxel <5
- Ribociclib + Anastrozole/Exemestane/Letrozole 0
- Ribociclib + Fulvestrant 0
- Talazoparib not in data
- Transtuzumab + Paclitaxel 0 (combination + pertuzumab = <5)
- Transtuzumab as a single agent 14
- Trastuzumab emtansine 0
- Any other active systemic anti-cancer therapy (see below)
 - carboplatin/paclitaxel <5
 - weekly paclitaxel <5
 - epirubicin/cyclophosphamide 20
 - 2 weekly accelerated paclitaxel 5
 - pertuzumab/trastuzumab <5
 - carboplatin single agent <5
 - docetaxel/carboplatin <5
 - capecitabine <5
 - docetaxel single agent <5

Less than five replaces the actual data as this could potentially identify individuals and would be exempt under section 38(1)(b) of FOISA.